Abilify Tablet
Product Images NDC 59148-010

16 FDA label images from Otsuka America Pharmaceutical, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Abilify (NDC 59148-010). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Otsuka America Pharmaceutical, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Abilify 01)

Chemical Structure (Abilify 01)
Chemical structure of aripiprazole, showing its molecular framework including two chlorine atoms, multiple ring systems, and functional groups associated with the active ingredient.*
FDA Label Image

Figure 1 (Abilify 02)

Figure 1 (Abilify 02)
A chart titled 'Effect of Other Drugs on Abilify' showing the fold change and 90% confidence intervals of aripiprazole pharmacokinetics (AUC and Cmax) when coadministered with various drugs. The x-axis represents change relative to reference without interacting drug, while the y-axis lists CYP3A4 and CYP2D6 inhibitors and inducers, gastric acid blockers, and others like valproate, lithium, and lorazepam.*
FDA Label Image

Figure 2 (Abilify 03)

Figure 2 (Abilify 03)
A pharmacokinetic chart showing the effect of various drugs on aripiprazole plasma levels, measuring fold change and 90% confidence intervals for AUC and Cmax relative to a reference without interacting drug. It includes CYP3A4 and CYP2D6 inhibitors and inducers, gastric acid blockers, and other drugs.*
FDA Label Image

Figure 3 (Abilify 04)

Figure 3 (Abilify 04)
A chart titled 'Effect of Abilify on Other Drugs' showing fold changes and 90% confidence intervals in pharmacokinetic (PK) parameters such as AUC and Cmax for various drugs including dextromethorphan, S-warfarin, R-warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, O-desmethylvenlafaxine, and escitalopram. The x-axis represents change relative to reference (without interacting drug) from 0.5 to 3.0, with most points around 1.0.*
FDA Label Image

Figure 4 (Abilify 05)

Figure 4 (Abilify 05)
A pharmacokinetic chart showing aripiprazole fold change and 90% confidence intervals for special populations, including CYP2D6 metabolizer status, gender, age groups, hepatic and renal impairment. The x-axis represents change relative to reference values, with data points for AUC and Cmax comparisons across these groups.*
FDA Label Image

Figure 5 (Abilify 06)

Figure 5 (Abilify 06)
A scatter plot chart illustrating the fold change and 90% confidence interval of dehydro-aripiprazole pharmacokinetic parameters (AUC and Cmax) relative to reference across different variables: CYP2D6 metabolizer status, gender, age groups, and levels of hepatic and renal impairment. The x-axis shows the change relative to reference values, while the y-axis lists these comparison factors.*
FDA Label Image

Figure 6 (Abilify 07)

Figure 6 (Abilify 07)
A line graph comparing the proportion with relapse over days from randomization between ABILIFY and placebo groups. The x-axis represents days (0 to 182) and the y-axis shows the proportion with relapse (0 to 1.0). Two curves depict relapse rates for ABILIFY (solid line) and placebo (dashed line), with ABILIFY showing a lower relapse proportion over time. A table under the x-axis lists the number of subjects at risk for both groups at multiple time points.*
FDA Label Image

Figure 7 (Abilify 08)

Figure 7 (Abilify 08)
A line graph comparing the proportion of relapse over time between ABILIFY and placebo groups. The x-axis shows days from randomization (0 to 182), and the y-axis represents the proportion with relapse (0.0 to 1.0). Two lines track the relapse proportion for ABILIFY and placebo, with numbers of subjects at risk indicated below the x-axis.*
FDA Label Image

Figure 8 (Abilify 09)

Figure 8 (Abilify 09)
A line graph showing the proportion with relapse over time in days from randomization comparing ABILIFY and placebo. The x-axis represents days from 0 to 364, with the number of subjects at risk noted below. The y-axis represents the proportion with relapse from 0.0 to 1.0. The ABILIFY line shows a consistently lower relapse proportion than the placebo line throughout the study period.*
FDA Label Image

Figure 9 (Abilify 10)

Figure 9 (Abilify 10)
A line graph titled 'Change in YGTSS Total TIC Score from Baseline' showing least-squares mean change in YGTSS total TIC score over 8 weeks of treatment. It compares three groups: ABILIFY low dose, ABILIFY high dose, and placebo. The graph depicts decreasing tic scores over time, with both ABILIFY groups showing greater reductions than placebo.*
FDA Label Image

Ablify 2 mg Tablets (Abilify 2mg Bottle Label)

Ablify 2 mg Tablets (Abilify 2mg Bottle Label)
Label for ABILIFY (aripiprazole) 2 mg oral tablets, containing 30 tablets. The label shows the brand name ABILIFY prominently with the generic name aripiprazole underneath. It includes directions to dispense with medication guide and states prescription only (Rx only). The labeler is Otsuka America Pharmaceutical, Inc.*
FDA Label Image

Abilify 5 mg Tablets (Abilify 5mg Bottle Label)

Abilify 5 mg Tablets (Abilify 5mg Bottle Label)
ABILIFY 5 mg tablets packaging label for oral use by Otsuka America Pharmaceutical, Inc. The label shows the brand name, generic name aripiprazole, strength 5 mg, quantity of 30 tablets, and includes a note to dispense with medication guide. It also states prescription only (Rx only) and displays the NDC 59148-007-13.*
FDA Label Image

Abilify 10 mg Tablets (Abilify 10mg Bottle Label)

Abilify 10 mg Tablets (Abilify 10mg Bottle Label)
Packaging label for ABILIFY (aripiprazole) tablets, 10 mg strength, oral dosage form. The label indicates a quantity of 30 tablets and includes directions to dispense with a medication guide. The labeler is Otsuka America Pharmaceutical, Inc. The label features the product name and strength prominently, with a barcode and regulatory information visible.*
FDA Label Image

Abilify 15 mg Tablets (Abilify 15mg Bottle Label)

Abilify 15 mg Tablets (Abilify 15mg Bottle Label)
ABIlIFY (aripiprazole) 15 mg tablets label from Otsuka America Pharmaceutical, Inc. The label indicates a package of 30 tablets for oral use, labeled for prescription use only with a directive to dispense with a medication guide. The National Drug Code (NDC) number shown is 59148-009-13.*
FDA Label Image

Abilify 20 mg Tablets (Abilify 20mg Bottle Label)

Abilify 20 mg Tablets (Abilify 20mg Bottle Label)
ABILIFY (aripiprazole) 20 mg oral tablets packaging label showing a box containing 30 tablets. The label includes the NDC number 59148-010-13, directs to dispense with medication guide, and is marked Rx only. The labeler is Otsuka America Pharmaceutical, Inc.*
FDA Label Image

Abilify 30 mg Tablets (Abilify 30mg Bottle Label)

Abilify 30 mg Tablets (Abilify 30mg Bottle Label)
Packaging label for ABILIFY (aripiprazole) 30 mg tablets by Otsuka America Pharmaceutical, Inc. The label indicates a 30-tablet count and prescription-only status. The design features the brand and generic names prominently, along with dosing strength and a barcode on the right side.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.